Unlock regulatory insights with Watson. Learn More
Return to Docket

Methodological Considerations in Evaluation of Cancer as an Adverse Outcome Associated With Use of Non-Oncological Drugs and Biological Products in the Postapproval Setting; Public Meeting, Request for Comments

Type: Non-Rule Making
Center CDER

Primary Documents (3)